Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

AngioDynamics, Inc. (ANGO)

Compare
10.86
+1.20
+(12.42%)
At close: April 2 at 4:00:01 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. James C. Clemmer CEO, President & Director 1.61M -- 1964
Mr. Stephen A. Trowbridge Executive VP & CFO 764.27k -- 1974
Mr. Chad T. Campbell Senior VP & GM of Oncology and Interventional Devices 592.76k -- 1971
Mr. Warren G. Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain 625.37k -- 1969
Ms. Laura Piccinini Senior VP & GM of Cardiovascular and International 706.93k -- 1969
Mr. Saleem M. Cheeks Vice President of Communications -- -- --
Mr. Benjamin H. Davis Senior Vice President of Business Development & Strategy -- -- 1964
Ms. Marna I. Bronfen-Moore Senior Vice President of Human Resources -- -- 1967
Ms. Kim L. Seabury Senior Vice President of Information Technology -- -- 1967
Mr. Juan Carlos Serna Senior Vice President of Scientific & Clinical Affairs -- -- --

AngioDynamics, Inc.

14 Plaza Drive
Latham, NY 12110
United States
518 795 1400 https://www.angiodynamics.com
Sector: 
Healthcare
Full Time Employees: 
748

Description

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

Corporate Governance

AngioDynamics, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 4. The pillar scores are Audit: 7; Board: 3; Shareholder Rights: 6; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 2, 2025 at 10:30 AM UTC

AngioDynamics, Inc. Earnings Date

Recent Events

April 2, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

January 16, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 8, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

November 15, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 8, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

October 23, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

October 3, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

September 26, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

July 25, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

July 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.